Steven Cohen Savara Inc Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.6 - $2.82 $3,302 - $5,820	2,064 New	2,064 $4,000
Q2 2020 Aug 14, 2020	SELL	$1.8 - $3.05 $1.63 Million - $2.77 Million	-907,464 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.91 - $4.08 $36,481 - $77,928	19,100 Added 2.15%	907,464 $1.92 Million
Q4 2019 Feb 14, 2020	BUY	$0.71 - $4.91 $630,738 - $4.36 Million	888,364 New	888,364 $3.98 Million
Q4 2018 Feb 14, 2019	SELL	$6.27 - $10.92 $4.47 Million - $7.79 Million	-713,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $7.48 Million - $9.18 Million	713,000 New	713,000 $7.96 Million

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.